NASDAQ: CERE

AbbVie (NYSE: ABBV) has announced its agreement to acquire Cerevel Therapeutics (NASDAQ: CERE) for approximately $8.7 billion, with the transaction expected to close in mid-2024, pending customary conditions. This acquisition is set to enhance AbbVie’s neuroscience portfolio by incorporating Cerevel’s promising drug candidates, which boast multibillion-dollar sales potential across various…